Atlas Trials

A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease

Clinical trial NCT06295679 · RECRUITING

Trial details

NCT number
NCT06295679
Sponsor
Amgen
Status
RECRUITING
Study type
OBSERVATIONAL
Major Cardiovascular EventEstablished Atherosclerotic Cardiovascular Disease
Start date
2022-12-19
Primary completion
2028-12-19
Enrollment
7000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.